Table 3 Comparison between pre-treatment SUV, post-treatment SUV, and % change in SUV (∆SUV) of the responder and non-responder groups
From: Role of PET/CT in post-therapeutic assessment of bronchogenic carcinoma
Responder group | Non-responder | P-value | |
|---|---|---|---|
Pre-treatment SUV | |||
Median | 14.6 | 10.9 | |
IQR | 11.8–17.7 | 4.95–20.7 | 0.396 |
Range | 10–20 | 3.5–34.7 | |
Post-treatment SUV | |||
Median | 5.6 | 11.8 | |
IQR | 2.8–6.3 | 6.3–19.4 | 0.014 |
Range | 0–8 | 2–28.2 | |
∆SUV | |||
Median | −63.1 | −14.0 | |
IQR | −83.1 to −53.4 | −32.8 to 54.9 | 0.0004 |
Range | −100 to −48.3 | −54 to 113.5 | |